Prospective Comparisons of Clinical Trial and Real-world Outcomes in Nasopharyngeal Carcinoma
NCT04108338 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5448
Last updated 2019-10-01
Summary
Study results from randomized controlled trials (RCTs) usually have been found not adequately inform practice. A RCT is optimized to determine efficacy, while real-world study is conducted in a routine care setting aimed to determine effectiveness. Thus, it is necessary to evaluate the pragmatism of clinical trials for a better understanding of the external generalizability. Nonetheless, comparative pragmatic features of RCTs and real-world studies still lack well elucidation. By capitalizing on a nasopharyngeal carcinoma (NPC)-specific big-data, real-world database and individual patient data extracted from three landmark RCTs, investigators conducted the direct comparison of NPC cohorts receiving same treatment strategy in clinical trial versus real-world settings, and examined the comparative pragmatic features and their influences on survival outcomes, safety profile, and the probability of returning to society.
Conditions
- Nasopharyngeal Carcinoma
Interventions
- OTHER
-
Trial setting
Study results from clinical trials usually have been found not work efficiently in clinical practice. This outcome disparity may be caused by different pragmatic features of medical environment, also known as study setting such as trial setting and real-world setting, in which biases inherent to clinical trial design restrict its applicability even though all confounding factors are avoided.
Sponsors & Collaborators
-
Sun Yat-sen University
lead OTHER
Principal Investigators
-
Jun Ma, Professor · Sun Yat-sen University
Eligibility
- Min Age
- 8 Years
- Max Age
- 79 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2019-06-01
- Primary Completion
- 2019-07-01
- Completion
- 2019-08-01
Countries
- China
Study Locations
More Related Trials
-
Retrospective Investigation of the Impacts of Prognosis for Nasopharyngeal Carcinoma Patients
NCT02604472 ·Status: COMPLETED
-
Surgery Plus Target-reduction Chemoradiotherapy vs Regular Chemoradiotherapy for Newly Diagnosed Resectable Nasopharyngeal Carcinoma
NCT05352321 ·Status: RECRUITING ·Phase: NA
-
Concurrent Chemotherapy for Recurrent T3/T4 Nasopharyngeal Carcinoma
NCT04136886 ·Status: RECRUITING ·Phase: PHASE3
-
Reduced-dose Radiotherapy for Low-risk Stage III Patients With Nasopharyngeal Carcinoma
NCT03668730 ·Status: UNKNOWN ·Phase: PHASE2
-
Chemotherapy Combined With Radiotherapy vs Chemotherapy Alone for Distant Metastatic Nasopharyngeal Carcinoma
NCT02111460 ·Status: UNKNOWN ·Phase: PHASE3
-
Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain
NCT05304468 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
IMRT Plus Cisplatin Versus IMRT in Patients With Stage 2 Nasopharyngeal Carcinoma
NCT03068936 ·Status: UNKNOWN ·Phase: PHASE3
-
Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab in the De Novo Metastatic Nasopharyngeal Carcinoma
NCT04398056 ·Status: UNKNOWN ·Phase: PHASE2
-
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition
NCT04436965 ·Status: RECRUITING ·Phase: PHASE3
-
Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT06669611 ·Status: RECRUITING ·Phase: PHASE3
-
A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT00705627 ·Status: UNKNOWN ·Phase: PHASE3
-
TPC Versus GP Induction Chemotherapy for Nasopharyngeal Carcinoma
NCT06301165 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC
NCT04833257 ·Status: COMPLETED ·Phase: PHASE2
-
To Study the Feasibility and Quality of Life of Medial Group Retropharyngeal Node Sparing in Nasopharyngeal Carcinoma
NCT03346109 ·Status: UNKNOWN ·Phase: NA
-
GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma
NCT03723343 ·Status: UNKNOWN
-
Endostar for Locally Recurrent Nasopharyngeal Carcinoma
NCT02636231 ·Status: UNKNOWN ·Phase: PHASE2
-
Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma
NCT06688760 ·Status: RECRUITING ·Phase: NA
-
Reducing Target Volumes in NPC Treated With Induction Chemotherapy Followed by Concurrent Chemoradiotherapy
NCT04384627 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Multicenter, Prospective, Phase III Randomized Controlled Clinical Study for the Treatment of N2-3 Nasopharyngeal Carcinoma Patients
NCT04061278 ·Status: UNKNOWN ·Phase: PHASE3
-
Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.
NCT07201337 ·Status: RECRUITING ·Phase: PHASE3
-
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
NCT06455410 ·Status: RECRUITING ·Phase: PHASE2
-
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
NCT06235203 ·Status: RECRUITING ·Phase: PHASE3
-
Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma
NCT06630780 ·Status: RECRUITING ·Phase: NA
-
A Trial On 4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation In N2-3 Nasopharyngeal Carcinoma
NCT02512315 ·Status: UNKNOWN ·Phase: PHASE3
-
CNG Staging Compared With 8th UICC of NPC for Treatment Decision-marking and Selection of Chemotherapy and Radiotherapy
NCT03529279 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3